Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical CoKKPCF 62 EV-to-EBITDA is 16.73 as of Jul. 28, 2026, which is 167% above its 10-year median of 6.27. GuruFocus rates KKPCF with a GF Score™ of 62/100 and a GF Value™ of $25.52. The stock has 2 warning signs investors should review. Among 743 Drug Manufacturers companies, Kaken Pharmaceutical Co ranks worse than 63.93% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kaken Pharmaceutical Co's enterprise value is $621.0 Mil.
Kaken Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $37.1 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-EBITDA for today is 16.73.
The historical rank and industry rank for Kaken Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
KKPCF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -62.87 Med: 6.27 Max: 23.73
Current: 17.68
During the past 13 years, the highest EV-to-EBITDA of Kaken Pharmaceutical Co was 23.73. The lowest was -62.87. And the median was 6.27.
KKPCF's EV-to-EBITDA is ranked worse than 63.93% of 743
companies
in the Drug Manufacturers industry
Industry Median: 12.94
vs KKPCF: 17.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Kaken Pharmaceutical Co (OTCPK:KKPCF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kaken Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Kaken Pharmaceutical Co's share price for today is $26.00.
Kaken Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.371.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaken Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kaken Pharmaceutical Co's EV-to-EBITDA falls into.
Kaken Pharmaceutical Co's current Enterprise Value is $621.0 Mil.
Kaken Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $37.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co (KKPCF) has a EV-to-EBITDA of 16.73 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kaken Pharmaceutical Co. This is 167% above median its historical median of 6.27. According to the industry distribution chart, Kaken Pharmaceutical Co ranks #475 out of 743 companies in the Drug Manufacturers industry, placing it in the top 63.9%.
Is Kaken Pharmaceutical Co's EV-to-EBITDA too high?
Kaken Pharmaceutical Co's current EV-to-EBITDA of 16.73 is 167% above median its 10-year median of 6.27. The Drug Manufacturers industry median EV-to-EBITDA is 12.94. Kaken Pharmaceutical Co's value of 16.73 is 29.3% above this industry median. Based on the distribution chart, Kaken Pharmaceutical Co ranks #475 out of 743 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kaken Pharmaceutical Co has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kaken Pharmaceutical Co ranks #475 out of 743 companies for EV-to-EBITDA. This places Kaken Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 12.94. Kaken Pharmaceutical Co's value of 16.73 is 29.3% above this benchmark. While the company's 10-year median is 6.27 vs. the industry median of 12.94, Kaken Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.94, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaken Pharmaceutical Co's current EV-to-EBITDA of 16.73 is 29.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kaken Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaken Pharmaceutical Co's current EV-to-EBITDA is 16.73, which is 167% above median its own 10-year median of 6.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Kaken Pharmaceutical Co (KKPCF) has a current EV-to-EBITDA of 16.73. The stock's GF Value™ is $25.52, compared to a current price of $26.00 — trading 1.9% above its estimated fair value. The current EV-to-EBITDA is 16.73, which is 167% above median its 10-year median of 6.27 and 29.3% above the Drug Manufacturers industry median of 12.94. Kaken Pharmaceutical Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kaken Pharmaceutical Co (KKPCF), the current EV-to-EBITDA is 16.73 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (KKPCF) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of $26.00 is trading 1.9% above its estimated GF Value™ of $25.52.
Key valuation signals for KKPCF:
EV-to-EBITDA: 16.73 (167% above median its 10-year median of 6.27)
GF Value™: $25.52 vs. price of $26.00 (1.9% above fair value)
Industry Position: 29.3% above the Drug Manufacturers median (#475 of 743)
No single metric tells the full story. See the KKPCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
62GF Score
Get the complete analysis for KKPCF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KKPCF has been successfully added to your 
